Journal of medical economics · 2026
The economic burden of moderate-to-severe rheumatoid arthritis in Spain: the CIARA study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silva-Fernández Lucía, Balsa Criado Alejandro, Sanmartí Raimon, Pérez Venegas José Javier, López-González Ruth, Castaño Sánchez Manuel, Cáliz Cáliz Rafael, Membrive Jiménez Cristina, Marras Fernández-Cid Carlos, Sánchez-Fernández Simón Ángel, Gómez Castro Susana, Vegas-Revenga Nuria, Sivera Mascaró Francisca, Mena Vázquez Natalia, Belmonte Ángeles, Ruiz Díaz Miguel Ángel, Rejas-Gutiérrez Javier, De Lossada Juste Alfonso, Montoro Álvarez María
Аннотация
AIMS: The CIARA (Cost Impact Analysis in Rheumatoid Arthritis patients) study in Spain aimed to assess societal costs (€2022) associated with adult patients with moderate-to-severe rheumatoid arthritis (RA) starting advanced therapies after failing conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or a first biologics (bDMARD). Costs included those incurred by the Spanish National Health System, indirect costs due to productivity losses, and patient out-of-pocket expenses. Secondary objectives were to compare costs according to patients' disease activity and treatment subgroups, identify variables associated with costs, and conduct a cost-utility analysis (CUA) of switching strategies.
METHODS: This prospective, non-interventional, multicenter cohort included adults with active RA (Disease Activity Score in 28 joints with erythrocyte sedimentation rate ≥3.2) starting a bDMARD or a targeted synthetic DMARD (tsDMARD) and followed for 12 months. Total and disaggregated mean costs per patient were estimated across three periods: 6 months before, and 0-to-6 months and 6-to-12 months post-switch. Costs for the 6-month pre-switch were compared with those for the 6-to-12 post-switch.
RESULTS: A total of 118 patients (mean age: 54.9 years; 78% women) were included. Mean total cost per patient increased from €6,882 pre-switch to €9,927 at 6-12 months (+44.3%;p < 0.001), primarily driven by pharmacological costs (+191%), while out-of-pocket expenses (-55%;p = 0.001) and productivity losses (-25%;p = 0.394) decreased. Switching from a csDMARD was dominant vs. switching from a first bDMARD (-€11,281/quality-adjusted life year [QALY] gained). Patients who achieved remission at 12 months had lower costs than those with moderate-high activity. The Work Productivity and Activity Impairment (WPAI) productivity impairment subscale and patient satisfaction with care were independently associated with total costs.
LIMITATIONS: Observational design, limited power for subgroups, official-actual price gap, and a 1-year horizon.
CONCLUSIONS: Switching to advanced therapies reduced out-of-pocket expenses and productivity losses. Although this reduction did not offset higher pharmaceutical spending, it may reflect clinical improvements.
METHODS: This prospective, non-interventional, multicenter cohort included adults with active RA (Disease Activity Score in 28 joints with erythrocyte sedimentation rate ≥3.2) starting a bDMARD or a targeted synthetic DMARD (tsDMARD) and followed for 12 months. Total and disaggregated mean costs per patient were estimated across three periods: 6 months before, and 0-to-6 months and 6-to-12 months post-switch. Costs for the 6-month pre-switch were compared with those for the 6-to-12 post-switch.
RESULTS: A total of 118 patients (mean age: 54.9 years; 78% women) were included. Mean total cost per patient increased from €6,882 pre-switch to €9,927 at 6-12 months (+44.3%;p < 0.001), primarily driven by pharmacological costs (+191%), while out-of-pocket expenses (-55%;p = 0.001) and productivity losses (-25%;p = 0.394) decreased. Switching from a csDMARD was dominant vs. switching from a first bDMARD (-€11,281/quality-adjusted life year [QALY] gained). Patients who achieved remission at 12 months had lower costs than those with moderate-high activity. The Work Productivity and Activity Impairment (WPAI) productivity impairment subscale and patient satisfaction with care were independently associated with total costs.
LIMITATIONS: Observational design, limited power for subgroups, official-actual price gap, and a 1-year horizon.
CONCLUSIONS: Switching to advanced therapies reduced out-of-pocket expenses and productivity losses. Although this reduction did not offset higher pharmaceutical spending, it may reflect clinical improvements.